NCT06903702View on ClinicalTrials.gov

A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine (AZA)

given daily for 7 days starting on Day 1 of each Cycle

DRUG

Venetoclax

orally daily for 28 days

PROCEDURE

Allogeneic hematopoietic stem cell transplantation

After the conditioning treatment, the HSCT procedure is part of standard care on Day 0.

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11725

RECRUITING

Memorial Sloan Kettering Cancer Center - Suffolk (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Consent and Follow-up), Middletown

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER